Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of WP-1303 vs ripasudil in primary open-angle glaucoma or ocular hypertension
jRCT2080224836Phase 3Terminated
- Sponsor
- Wakamoto Pharmaceutical
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ripasudil + brimonidine in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Wakamoto Pharmaceutical. Started Aug 2019; status: terminated.
02
Drugs
ripasudil + brimonidine
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2080224836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224836.